Theorem Clinical Research

Global News

Stuart Horowitz appointed to ACRP editorial advisory board

Thursday, February 26, 2015 01:09 PM

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software to support clinical research, has announced that Stuart Horowitz, Ph.D., M.B.A., its president of institutions and institutional services, has been appointed to the Association of Clinical Research Professionals' (ACRP's) editorial advisory board for a two-year term.

More... »

Quest Diagnostics

Quintiles named to Fortune magazine's 2015 list of World’s Most Admired Companies

Thursday, February 26, 2015 01:05 PM

Quintiles, a biopharmaceutical services company, has been named to Fortune magazine’s World’s Most Admired Companies list for 2015.

More... »


Palatin launches web site in support of phase III program for female sexual dysfunction

Thursday, February 26, 2015 12:15 PM

Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, has launched a clinical trial web site (https://www.reconnectstudy.com) in support of its phase III reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).

More... »

BIO launches 2015 Everyday Superhero Contest

Thursday, February 26, 2015 11:00 AM

The Biotechnology Industry Organization (BIO) has announced a new contest aimed at recognizing biotech superheroes in the patient, industry and academic communities. Nominations will be accepted until March 5 for each of three categories: Patient/Patient Group, Pharma/Biotech and University/Research Institutions. Winners will be chosen by popular vote by March 31, and announced on site at the 2015 BIO International Convention, June 15-18 in Philadelphia, Pa.

More... »

Omeros's phase II OMS721 trial completes dosing, extended access for compassionate use

Thursday, February 26, 2015 10:45 AM

Omeros has completed dosing of the low-dose cohort of patients in its ongoing phase II clinical trial evaluating the efficacy and safety of OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, in treating thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.

More... »

Sosei acquires Heptares Therapeutics for up to $400M

Wednesday, February 25, 2015 11:36 AM

Sosei Group, a Japanese biopharmaceutical company with operations in Japan and the U.K., has acquired Heptares Therapeutics, a clinical-stage, private U.K.-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors (GPCRs).

More... »

Turing Pharmaceuticals launched

Wednesday, February 25, 2015 11:32 AM

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

More... »

Report: Global oncology drugs market is expected to reach $111.9B by 2020

Wednesday, February 25, 2015 11:31 AM

The global oncology market is forecasted to reach $111.9 billion by 2020, registering a CAGR of 7.1% from 2014 to 2020, according to a new report by Allied Market Research, titled Global Oncology/Cancer Drugs Market—Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013-2020.

More... »

Ipsen to acquire Canbex Therapeutics for $10.2M

Wednesday, February 25, 2015 11:29 AM

Canbex Therapeutics has granted Ipsen, a global specialty-driven pharmaceutical company headquartered in Paris, the exclusive right to purchase 100% of Canbex shares upon completion of the phase IIa study of Canbex’s lead candidate VSN16R for the treatment of spasticity in people with multiple sclerosis (MS).

More... »

Shire acquires Meritage Pharma

Wednesday, February 25, 2015 11:27 AM

Shire has acquired Meritage Pharma, a global, privately held company, for $70 million upfront and additional contingent payments based on development and regulatory milestones.

More... »

`

CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs